Fund­ed for PhII, biotech en­tre­pre­neurs achieve a 15-year-old R&D dream

Niels Riede­mann and Ren­feng Guo fol­lowed en­tire­ly dif­fer­ent paths, but 15 years ago both wound up work­ing to­geth­er in the lab of Pe­ter Ward at the Uni­ver­si­ty of Michi­gan, a promi­nent in­ves­ti­ga­tor known for his land­mark re­search on the C5 path­way. That ear­ly team­work cre­at­ed a bond over their in­sights in­to a par­tic­u­lar av­enue of the path­way that they hope will lead to a first-in-class an­ti-in­flam­ma­to­ry drug. And they have now raised their first big chunk of cash — $34 mil­lion — to put it to its first big Phase II proof-of-con­cept chal­lenge.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.